• 孙丽萍

    药物化学系 教授
    领域:新药分子设计与合成研究
    联系电话:
    电子邮箱:chsunlp@163.com
    办公室:江宁校区学院实验楼535室
    实验室:江宁校区学院实验楼529北
  • 1、教育经历
    (1) 2001/09-2004/07, 香港科技大学, 有机化学,博士
    (2) 1988/09-1991/07,中科院兰州化学物理研究所,有机化学,硕士
    (3) 1984/09-1988/07, 西北师范大学,化学,学士
    2、工作经历
    (1) 2008/10 -至今, 我校, 3499cc拉斯维加斯入口, 教授
    (2) 2005/01-2006/01, 新加坡国立大学, 化学系, 博士后
    (3) 1991/06-2006/01,西北师范大学,化学系,讲师,副教授
    3、学术荣誉
    2010/06,江苏省高校“青蓝工程”中青年学术带头人
    (1) 基于炎症和抗肿瘤药物的设计与评价研究
    (2) 活性天然产物的结构改造和成药性优化研究
    (3) 金属催化的小分子药物的合成方法学研究
    1、科研项目
    (1)江苏省科技厅,江苏省自然科学基金,BK20181333,江苏省自然科学基金,新型FGFR4特异性共价抑制剂的设计、合成及抗肝癌活性研究,2018-7 至 2021-06,10万元,已结题,主持
    (2)国家自然科学基金面上项目,214722437,,新型基于吡咯[4,3,2-de]喹啉类STAT3抑制剂的设计、合成与抗肿瘤活性研究,2015-01-01 至 2015-12-31,40万元,已结题,主持
    (3)国家自然科学基金面上项目,21172265,基于DFG-out型VEGFR/FGFR双重抑制剂的设计、合成及血管生成抑制活性的研究,2012-01至2015-12,60万元,已结题,主持
    (4)2010年江苏省高校”青蓝工程“中青年学术带头人
    2、学术获奖
    (1)2018年,江苏省教育教学与研究成果奖,排名第三
    1.Li W, Zhang C, Zhang H-e, Dong R, Liu J-y, Wang C-m, Wang M, Wang Y-w, Wang C, Zhang Y, Shi L, Xu Y, Sun L-P, Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors[J]. Bioorganic Chemistry, 2022, 127: 105917. (IF:5.307)
    2.Li W, Zhang J-y, Wang M, Dong R, Zhou X, Zheng X, Sun L-P. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery[J]. Current Topics in Medicinal Chemistry, 2022, 22(4): 284-304. (IF:3.57)
    3.Dong R, Zhang C, Wang C, Zhou X, Li W, Zhang J-Y, Wang M, Xu Y, Sun L-P. Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors[J]. Bioorganic & Medicinal Chemistry, 2022, 55: 116592. (IF:3.461)
    4.Dong R, Zhou X, Wang M, Li W, Zhang J-Y, Zheng X, Tang K- x, Sun L-P. Discovery of 4-amino-1H-pyrazolo [3, 4-d] pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors[J]. Bioorganic & Medicinal Chemistry, 2021, 29: 115876. (IF:3.461)
    5.Tang K- x, Wang C-M, Gao T-H, Chen L, Fan L, Sun L-P. Transition Metal‐Catalyzed C− H Bond Functionalizations by Use of Sulfur‐Containing Directing Groups[J]. Advanced Synthesis & Catalysis, 2019, 361(1): 26-38. (IF: 5.451)
    6.Wang C-M, Tang K- X, Gao T-H, Chen L, Sun L-P. Cu (II)-Catalyzed Ortho-C–H Nitration of Aryl Ureas By C–H Functionalization[J]. The Journal of Organic Chemistry, 2018, 83(15): 8315-8321. (IF: 4.748)
    7. Xue Y, Song P-R, Song Z-L, Wang A-L, Tong L-J, Geng M-Y, Ding J, Liu Q-S, Sun L-P, Xie H, Zhang A. Discovery of 4, 7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido [5, 4-b] pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors[J]. Journal of Medicinal Chemistry, 2018, 61(10): 4608-4627. (IF: 6.054)
    8.Tang K., Chun-Meng Wang, Tian-Hong Gao, Cong Pan and Sun L-P,, Pd-catalyzed C–H arylation of benzothioamides with boronic acids using thioamides as directing groups, Org. Chem. Front., 2017, 4(11), 2167-2169.(IF: 5.455)
    9.Zhang H.,F. Gong,J.g Ye,C. Zhang,X. Yue, C. Li,Yun-.n Xu, Sun L-P,, Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2., Eur. J. Med. Chem.,2017,125,245-254. (IF:4.816)
    Zhang H., F. Gong, C. Li, C. Zhang, Y. Wang, Y. Xu, Sun L-P, Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors,Eur. J. Med. Chem., 2016, 109,371-379.(IF: 4.519)
    Baidu
    sogou